Bilakhia Group, one of India’s leading diversified business conglomerates is playing a pivotal role in combating COVID-19 through innovation, not just in India but globally. In its latest development, Bilakhia Group’s India-based global medical device company, Meril, has been granted approval by the Indian Council of Medical Research for its ground-breaking COVID Rapid Antigen Test kit (RAT).
‘CoviFind’ by Meril is a self-use Rapid Antigen Test for COVID-19. The test is capable of detecting the SARS-CoV-2 virus in infected individuals just within 15 minutes, making it an effective tool in testing symptomatic individuals as well as those individuals who have come in close contact with infected patients.
CoviFind is one of the many medical breakthroughs achieved by Meril, established in 2007, Meril manufactures advanced medical devices and diagnostics technologies in the range of vascular interventions, structural heart interventions, orthopedic implants, ENT devices, endo-surgical devices, and a wide range of in-vitro diagnostics (IVD). Meril envisions augmenting the healthcare infrastructure and alleviating human suffering through its steadfast commitment in large-scale R&D and manufacturing of medical devices.
